PharmaShots | Incisive News in 3 Shots

Subscribe Now

Resected High-Risk Melanoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Priority Review for the Adjuvant Treatment of Stage II Resected High-Risk Melanoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Priority Review for the Adjuvant Treatment of Stage II Resected High-Risk M...

August 5, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us